• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

UK Startup Flow Launches Chatbot Therapist to Combat Depression

by Jasmine Pennic 09/27/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
UK Startup Flow Launches Chatbot Therapist to Combat Depression

– UK startup launches Flow, a chatbot therapist engages users with daily chat conversations and offers self-help techniques, mood tracking, curated videos, meditation, and mental exercises.


– Available to download free on iOS, the chatbot therapist is based on the latest psychology and neuroscience research and was developed by clinical psychologists and machine learning experts.


– To maximize the chance of recovery, Flow can be used in conjunction with the Flow brain stimulation headset.


Flow, a London-based medical device company has announced the launch of its chatbot therapist to treat depression. The chatbot therapist, called Flow, engages users with daily chat conversations and offers self-help techniques, mood tracking, curated videos, meditation, and mental exercises. It helps users to learn why sleep, exercise, nutrition, and meditation are the main pillars in recovering from depression – and gathers mood data to offer a personalized response modeled on behavioral therapy. 

Impact of Mental Illness in the UK

Nearly one in four adults in the UK are affected by mental illness. Suicide is the most common cause of death for men aged 20-49 years in England and Wales. The economic costs of mental illness in England is estimated at £105.2 billion annually. And one in three work sickness notes handed out by GPs are for mental health reasons, including depression.

“Accessibility and early intervention in depression is crucial,” says Daniel Mansson, Clinical Psychologist, CEO and Co-Founder of Flow. “The ‘always-on’ source of therapy provided by Flow ensures people get the help they need as quickly as possible. Flow can provide anonymity without the fear of being judged by others. This is great as some people feel anxious when it comes to talking about their depression to another human.”

Brain Stimulation Headset

Flow Launches Medical-Grade Headset, Therapy App for Depression

To maximize the chance of recovery, Flow can be used in conjunction with the Flow brain stimulation headset. Randomized controlled trials published in the New England Journal of Medicine and the British Journal of Psychiatry show that brain stimulation, of the type used in the Flow headset, had a similar impact to antidepressants but with fewer and less-severe side effects.  The Flow headset retails at £399 and can be purchased here.

The brain stimulation headset is the first and only medically approved treatment for depression of its kind in Europe. Classified as a Class IIa medical device, Flow was developed from the fields of clinical psychology, neuroscience and innovative technology including machine learning. Flow empowers and motivates individuals to take control and self-manage their depression with effective, non-pharmacological, digital alternatives.

Flow Availability

Available to download free on iOS, the chatbot therapist is based on the latest psychology and neuroscience research and was developed by clinical psychologists and machine learning experts. An Android version will be available on October 2019. The Flow chatbot therapist requires iOS 11.0 or later. Compatible with iPhone, iPad and iPod touch. Users must be at least 17 years old to download this application

Flow is starting talks with the NHS to have its brain stimulation headset available on prescription. The company recently announced an investment of £1.2 million by Khosla Ventures to roll out it’s offering across Europe, introduce the Flow headset to healthcare clinics in the UK, and fund clinical studies.

The Landscape of Mental Health Chatbots in the UK

Flow joins a growing number of mental health chatbots, including Woebot and Wysa, which are playing an increasing role in the mental health landscape. Whilst Woebot and Wysa use a cognitive behavioral approach to change the way people think, Flow has one goal: to reduce clinical depression based on well-grounded science.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Chatbot in Healthcare, Depression, Depression Mobile Health Apps, Khosla Ventures, Machine Learning, Medical Device, Mental Health, Mental Illness, NHS

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |